Endometrial Cancer Causes
Endometrial Cancer Causes
Endometrial cancer has one of the clearest causal stories in oncology: the lining grows under estrogen, and cancer follows when estrogen acts for years without progesterone to check it. Weight, hormonal history and a small number of genes decide who sits in that hormonal environment the longest.
Unopposed estrogen — the central mechanism
The endometrium is a two-hormone system. Estrogen makes the lining grow; progesterone stops the growth and stabilises it. Every month the two alternate, and the lining is shed. Cancer becomes possible when estrogen acts for long stretches with no progesterone to counter it — the state clinicians call unopposed estrogen. The lining grows disordered, cells accumulate changes, and hyperplasia — then cancer — can follow.
Almost every established risk factor is a route into that state. Pregnancy floods the body with progesterone for months, which is why never having been pregnant raises risk. Late menopause extends the years of cycling. Estrogen-only hormone replacement — given without the opposing progestin — acts directly. Obesity manufactures estrogen inside fat tissue after the ovaries stop. Polycystic ovary syndrome withholds ovulation, and with it the progesterone surge. Seen this way, the risk list is not a list at all: it is one mechanism arriving by six doors.
The corollary matters for prevention: anything that restores the progesterone counterweight — pregnancy, the combined contraceptive pill, progestin-releasing intrauterine devices — lowers risk. The mechanism that explains the disease also explains its prevention.
Obesity and the hormonal pathway
Obesity deserves its own section because it is the strongest modifiable risk factor for this disease, and the mechanism is concrete rather than statistical. After menopause the ovaries stop making estrogen — but fat tissue contains the enzyme aromatase, which converts androgens from the adrenal glands into estrogen. More fat tissue means more estrogen, produced continuously, with no progesterone anywhere near it. The postmenopausal woman with obesity is living inside the unopposed-estrogen state by default.
The association is strong and dose-dependent: risk rises with each increment of weight, and weight loss after menopause measurably lowers the estrogen level. This is also why endometrial cancer incidence tracks the obesity curve in country after country — and why the disease, though commonest in the sixties and seventies, is appearing at younger ages where obesity is common.
Two honest framing points. First, most women with obesity do not develop endometrial cancer — the mechanism raises probability, it does not determine it. Second, the message is not blame but leverage: weight is the one input on the whole risk list a patient can move, and it moves the risk of several other cancers at the same time.
Lynch syndrome and family history
Around 5% of endometrial cancers arise in Lynch syndrome, an inherited condition in which one copy of a DNA mismatch-repair gene does not work from birth. Cells with a single working copy manage — until the second copy is damaged by chance, after which repair errors accumulate and cancers follow. Lynch syndrome raises the risk of colon cancer above all, and endometrial cancer is its commonest manifestation in women — often arriving before the colon does.
The practical implications are specific. Women with Lynch syndrome are offered annual surveillance of the lining from age 35, and many consider risk-reducing hysterectomy once childbearing is complete — decisions made with a genetics team, not improvised. And because the condition is inherited, every diagnosis of endometrial cancer in a woman under 60, and any case with colon cancer in the family, is a prompt for mismatch-repair testing of the tumour — the same test that already guides immunotherapy. Finding Lynch syndrome changes the surveillance plan for the patient herself, and for her children and siblings.
Tamoxifen and hormone therapy
Tamoxifen — the hormone tablet taken for years after breast cancer — blocks estrogen receptors in breast tissue but acts mildly estrogenic on the endometrium. It raises the risk of endometrial cancer and of polyps, in a dose- and duration-dependent way. The risk is real but modest, and for most women the benefit against breast cancer recurrence far outweighs it — the answer is not to stop tamoxifen but to take its gynaecological side seriously: any abnormal bleeding during tamoxifen gets the same ultrasound-and-biopsy work-up as any postmenopausal bleeding, without exception. Routine extra screening beyond symptom-triggered assessment is not recommended and is not a substitute for reporting bleeding.
Hormone replacement therapy divides by composition. Estrogen-only therapy — appropriate only for women who have had a hysterectomy, since they have no uterus to protect — raises endometrial cancer risk precisely because it is unopposed. Combined therapy, estrogen with a progestin, restores the counterweight and does not carry the same risk. Women on either regimen should still report bleeding promptly: therapy explains some bleeding, but never all of it.
What does not cause it
Several beliefs circulate that the evidence does not support:
- Infection — no infection causes endometrial cancer. This distinguishes it from cervical cancer (HPV-driven); the two diseases share an organ region but nothing else. It is not contagious and cannot be caught or transmitted.
- Fertility treatment — ovulation-inducing drugs have been studied extensively; the current evidence does not show them raising endometrial cancer risk independent of the infertility itself.
- Intrauterine devices — the progestin-releasing device lowers endometrial cancer risk; copper devices show no increase.
- Stress or a blow to the body — trauma and psychological stress have no established role in causing this cancer.
- A single late or heavy period — one anomalous cycle, particularly in perimenopause, is overwhelmingly hormonal and not a cancer signal by itself; it is the pattern and persistence that matter.
Where beliefs like these delay care, they cost exactly what this cancer rewards — the early weeks in which a symptom leads to an ultrasound. The evidence-based list is short: estrogen exposure, weight, age, and genes.
Who is at higher risk
Bringing the sections together, the risk profile in plain terms — the disease is commonest after 50, and risk rises with any combination of:
- Obesity, especially after menopause
- Never having been pregnant
- Late menopause (after 55) or early first period
- Polycystic ovary syndrome or type 2 diabetes
- Estrogen-only hormone therapy (with the uterus in place) or long-term tamoxifen
- A family history of colon or endometrial cancer, or known Lynch syndrome
- Previous hyperplasia with atypia of the lining
Two groups deserve a standing arrangement rather than symptom-triggered care. Women with Lynch syndrome should have a genetics-led surveillance plan in place. And women with long-standing anovulation from polycystic ovary syndrome should make sure their irregular bleeding is actually investigated once, with an ultrasound, rather than accepted as their normal — the hormonal pattern that makes cycles irregular is the same one that lets the lining grow unopposed.